Business
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)
Amarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID).
About this update from Amarantus Bioscience Holdings, Inc.
[{"type":"text","content":"\n\n\n\nAmarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)\n\n\n\n\n\nAmarantus Receives Notice of Allowance for U.S. Patent Application Covering Method of Treating Parkinson's Disease Levodopa-induced Dyskinesia (PD-LID)\nPatent issuance will provide additional IP protection for eltoprazine, lead product candidate, through 2027\nPR Newswire\nSAN FRANCISCO, December 15, 2015\n\n\n\nSAN FRANCISCO, December 15, 2015 /PRNewswire/ --\n\n \n\nAmarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing products for Regenerative Medicine, Neurology and Orphan Diseases, announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) covering the use of combination 5HT1A and 5HT1B agonists, including eltoprazine, for the treatment of PD-LID. The USPTO issues a Notice of Allowance after it makes a determination that a patent should be issued based on examination of the filing. In the case of eltoprazine, AMBS' lead clinical stage product, the Notice will provide additional intellectual property protection through 2027. This Notice of Allowance was received for a patent application filed as a continuation in part to previously issued US Patent #9,066,903, and will further strengthen the Company's intellectual property protection against potential combination 5HT1A/1B receptor agonist competition for the treatment of PD LID.\n\nEltoprazine is a clinical Phase 2b stage small molecule targeted for the treatment of PD-LID. Enrollment for the current study is temporarily paused as the company awaits a decision from the US Food & Drug Administration on an orphan drug application submitted by Amarantus for the treatment of PD-LID that may alter the Company's development strategy. PD-LID is an abnormal involuntary movement disorder resulting from prolonged levodopa-based therapy, the most commonly prescribed treatment for Parkinson's disease. PD-LID is one of the most difficult problems facing people with the disease. Dyskinesia can be severely disabling and can impact quality of life by prohibiting the ability to perform routine daily functions.\n\n\"This Notice of Allowance for eltoprazine in Parkinson's disease levodopa-induced dyskinesia significantly strengthe...